PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.65%
R&D reduction while TRVN shows 18.31% growth. Joel Greenblatt would examine competitive risk.
44.07%
G&A growth above 1.5x TRVN's 22.51%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
473.10%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
6.92%
Operating expenses growth less than half of TRVN's 19.19%. David Dodd would verify sustainability.
6.92%
Total costs growth less than half of TRVN's 19.19%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
473.10%
D&A growth while TRVN reduces D&A. John Neff would investigate differences.
73.55%
EBITDA growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-6.92%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
163.21%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
121.05%
Pre-tax income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
Net income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
121.15%
EPS growth exceeding 1.5x TRVN's 25.31%. David Dodd would verify competitive advantages.
115.11%
Diluted EPS growth exceeding 1.5x TRVN's 25.31%. David Dodd would verify competitive advantages.
2.25%
Share count reduction exceeding 1.5x TRVN's 64.31%. David Dodd would verify capital allocation.
42.15%
Diluted share reduction below 50% of TRVN's 64.31%. Michael Burry would check for concerns.